Samsung Biologics : Material Business Matters Related to Investment Decisions

Material Business Matters Related to Investment Decisions

1. Title	Biologics CMO Binding LOI contract
2. Details	1) The Other Party to the Contract : AstraZeneca UK Ltd. 2) Contract Amount(KRW) : 457,138,718,063 3) Revised Contract Date : 2022.08.11
3. Date of board resolution (decision date) or confirmation date	2022-08-11
- Attendance of outside directors	Present(No.)	-
Absent(No.)	-
- Attendance of auditors (members of Audit Committee who are not outside directors)	-
4. Other matters to be factored into investment decisions
- Samsung biologics signed a binding LOI for contract manufacturing on May 14th, 2021, and did not disclose the contract amount at the time as it did not meet the disclosure standards. Thereafter, a revised contract was executed due to an increase in the customer demand, and the confirmed contract amount increased to USD 350,970,225. - Contract Amount is based on the committed binding amount (USD 350,970,225) applied with the basic exchange rate(USD/KRW 1,302.50) published by Seoul Money Brokerage Services Ltd. at the opening business on August 12th, 2022. - Contract Amount is 29.15% of sales in the latest fiscal year (KRW 1,568,006,928,039). - Contract Amount is binding on the two companies under the contract, and when the main contract is concluded in the future, the confirmed details will be disclosed. - Contract Period is from LOI contract date to the main contract date.
※ Related disclosure	-